Oxidative stress, glutathione status, sirtuin and cellular stress response in type 2 diabetes

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1822, Issue 5, 2012, Pages 729-736

  Calabrese, V ^a   Cornelius, C ^a   Leso, V ^a,b   Trovato Salinaro, A ^a   Ventimiglia, B ^a   Cavallaro, M ^a   Scuto, M ^a   Rizza, S ^a   Zanoli, L ^a   Neri, S ^a   Castellino, P ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Cellular stress response; Glutathione status; Redox signaling; Sirtuins; Type 2 diabetes; Vitagenes

Indexed keywords

4 HYDROXYNONENAL; GLUTATHIONE; GLUTATHIONE DISULFIDE; HEAT SHOCK PROTEIN 70; HEME OXYGENASE 1; ISOPROSTANE DERIVATIVE; PENTOSIDINE; SIRTUIN; SIRTUIN 1; SIRTUIN 2; THIOREDOXIN REDUCTASE; THIOREDOXIN REDUCTASE 1;

ADULT; AGED; ARTICLE; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; FEMALE; HUMAN; LYMPHOCYTE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN INDUCTION;

ADULT; AGED; BLOTTING, WESTERN; DIABETES MELLITUS, TYPE 2; FEMALE; GLUTATHIONE; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; SIRTUINS;

EID: 84858152480     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.12.003     Document Type: Article

References (68)

1. Droge W. Free radicals in the physiological control of cell function. Physiol. Rev. 2002, 82:47-95.
2. Al Ghouleh I., Khoo N.K., Knaus U.G., Griendling K.K., Touyz R.M., Thannickal V.J., Barchowsky A., Nauseef W.M., Kelley E.E., Bauer P.M., Darley-Usmar V., Shiva S., Cifuentes-Pagano E., Freeman B.A., Gladwin M.T., Pagano P.J. Oxidases and peroxidases in cardiovascular and lung disease: new concepts in reactive oxygen species signaling. Free Radic. Biol. Med. 2011, 51:1271-1288.
3. Del Vecchio L., Locatelli F., Carini M. What we know about oxidative stress in patients with chronic kidney disease on dialysis-clinical effects, potential treatment, and prevention. Semin. Dial. 2011, 24:56-64.
4. Rains J.L., Jain S.K. Oxidative stress, insulin signaling, and diabetes. Free Radic. Biol. Med. 2011, 50:567-575.
5. Davì G., Falco A., Patrono C. Lipid peroxidation in diabetes mellitus. Antioxid. Redox Signal. 2005, 7:256-268.
6. Ceriello A. Oxidative stress and diabetes-associated complications. Endocr. Pract. 2006, 12:60-62.
7. Barlovic D.P., Soro-Paavonen A., Jandeleit-Dahm K.A. RAGE biology, atherosclerosis and diabetes. Clin. Sci. (Lond.) 2011, 121:43-55.
8. Bonnefont-Rousselot D., Bastard J.P., Jaudon M.C., Delattre J. Consequences of the diabetic status on the oxidant/antioxidant balance. Diabetes Metab. 2000, 26:163-176.
9. Tanji N., Markowitz G.S., Fu C., Kislinger T., Taguchi A., Pischetsrieder M., Stern D., Schmidt A.M., D'Agati V.D. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J. Am. Soc. Nephrol. 2000, 119:1656-1666.
10. Mullarkey C.J., Edelstein D., Brownlee M. Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem. Biophys. Res. Commun. 1990, 173:932-939.
11. Basta G., Schmidt A.M., De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc. Res. 2004, 63:582-592.
12. S.I. Yamagishi, S. Maeda, T. Matsui, S. Ueda, K. Fukami, S. Okuda, Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes, Biochim. Biophys. Acta (2011) [Electronic publication ahead of print].
13. Toyokuni S., Yamada S., Kashima M., Ihara Y., Yamada Y., Tanaka T., Hiai H., Seino Y., Uchida K. Serum 4-hydroxy-2-nonenal-modified albumin is elevated in patients with type 2 diabetes mellitus. Antioxid. Redox Signal. 2000, 2:681-685.
14. Pillon N.J., Vella R.E., Souleere L., Becchi M., Lagarde M., Soulage C.O. Structural and functional changes in human insulin induced by the lipid peroxidation byproducts 4-hydroxy-2-nonenal and 4-hydroxy-2-hexenal. Chem. Res. Toxicol. 2011, 24:752-762.
15. Miyata T., Sugiyama S., Suzuki D., Inagi R., Kurokawa K. Increased carbonyl modification by lipids and carbohydrates in diabetic nephropathy. Kidney Int. Suppl. 1999, 71:S54-S56.
16. Morrow J.D., Awad J.A., Boss H.J., Blair I.A., Roberts L.J. Non cyclo-oxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:10721-10725.
17. Patrono C., Falco A., Davì G. Isoprostane formation and inhibition in atherothrombosis. Curr. Opin. Pharmacol. 2005, 5:198-203.
18. Davì G., Ciabattoni G., Consoli A., Mezzetti A., Falco A., Santarone S., Pennese E., Vitacolonna E., Bucciarelli T., Costantini F., Capani F., Patrono C. In vivo formation of 8-iso prostaglandin F2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999, 99:224-229.
19. Roberts L.J., Morrow J.D. Measurement of F2-isoprostanes as an index of oxidative stress in vivo. Free Radic. Biol. Med. 2000, 28:505-513.
20. Basu S. Isoprostanes: novel bioactive products of lipid peroxidation. Free. Radic. Res. 2004, 38:105-122.
21. Milatovic D., Montine T.J., Aschner M. Measurement of isoprostanes as markers of oxidative stress. Methods Mol. Biol. 2011, 758:195-204.
22. Barden A., Mas E., Henry P., Durand T., Galano J.M., Roberts L.J., Croft K.D., Mori T.A. The effects of oxidation products of arachidonic acid and n3 fatty acids on vascular and platelet function. Free. Radic. Res. 2011, 45:469-476.
23. Cracowski J.L., Ormezzano O. Isoprostanes, emerging biomarkers and potential mediators in cardiovascular diseases. Eur. Heart J. 2004, 25:1675-1678.
24. Pignatelli P., Carnevale R., Di Santo S., Bartimoccia S., Sanguigni V., Lenti L., Finocchi A., Mendolicchio L., Soresina A.R., Plebani A., Violi F. Inherited human gp91phox deficiency is associated with impaired isoprostane formation and platelet dysfunction. Arterioscler. Thromb. Vasc. Biol. 2011, 31:423-434.
25. Calabrese V., Scapagnini G., Colombrita C., Ravagna A., Pennisi G., Giuffrida Stella A.M., Galli F., Butterfield D.A. Redox regulation of heat shock protein expression in aging and neurodegenerative disorders associated with oxidative stress: a nutritional approach. Amino Acids 2003, 25:437-444.
26. Calabrese V., Scapagnini G., Ravagna A., Colombrita C., Spadaro F., Butterfield D.A., Giuffrida Stella A.M. Increased expression of heat shock proteins in rat brain during aging: relationship with mitochondrial function and glutathione redox state. Mech. Ageing Dev. 2003, 125:325-335.
27. Calabrese V., Butterfield D.A., Scapagnini G., Stella A.M., Maines M.D. Redox regulation of heat shock protein expression by signaling involving nitric oxide and carbon monoxide: relevance to brain aging, neurodegenerative disorders, and longevity. Antioxid. Redox Signal. 2006, 8:444-477.
28. Calabrese V., Cornelius C., Dinkova-Kostova A.T., Calabrese E.J., Mattson M.P. Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders. Antioxid. Redox Signal. 2010, 13:1763-1811.
29. Calabrese V., Cornelius C., Giuffrida A.M., Calabrese E.J. Cellular stress responses, mitostress and carnitine insufficiencies as critical determinants in aging and neurodegenerative disorders: role of hormesis and vitagenes. Neurochem. Res. 2010, 35:1880-1915.
30. Collet J.F., Messens J. Structure, function, and mechanism of thioredoxin proteins. Antioxid. Redox Signal. 2010, 13:1205-1216.
31. Altschmied J., Haendeler J. Thioredoxin-1 and endothelial cell aging: role in cardiovascular diseases. Antioxid. Redox Signal. 2009, 11:1733-1740.
32. Guarente L., Franklin H. Epstein lecture: sirtuins, aging, and medicine. N. Engl. J. Med. 2011, 364:2235-2244.
33. Jr Adams J.D., Lauterburg B.H., Mitchell J.R. Plasma glutathione and glutathione disulfide in the rat: regulation and response to oxidative stress. J. Pharmacol. Exp. Ther. 1983, 227:49-54.
34. Ritov V.B., Kelley D.E., Kagan V.E. Derivatization of F2-isoprostanes with 1-pyrenyldiazomethane and their subsequent determination by fluorescence high-performance liquid chromatography. Anal. Biochem. 2002, 311:10-18.
35. Miyata T., Taneda S., Kawai R., Ueda Y., Horiuchi S., Hara M., Maeda K., Monnier V.M. Identification of pentosidine as a native structure for advanced glycation end products in beta-2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:2353-2358.
36. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., Fujimoto E.K., Goeke N.M., Olson B.J., Klenk D.C. Measurement of protein using bicinchoninic acid. Anal. Biochem. 1985, 150:76-85.
37. Reed T., Perluigi M., Sultana R., Pierce W.M., Klein J.B., Turner D.M., Coccia R., Markesbery W.R., Butterfield D.A. Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neurobiol. Dis. 2008, 30:107-120.
38. Calabrese V., Mancuso C., Sapienza M., Puleo E., Calafato S., Cornelius C., Finocchiaro M., Mangiameli A., Di Mauro M., Stella A.M., Castellino P. Oxidative stress and cellular stress response in diabetic nephropathy. Cell Stress Chaperones 2007, 12:299-306.
39. Sultana R., Butterfield D.A. Proteomics identification of carbonylated and HNE-bound brain proteins in Alzheimer's disease. Methods Mol. Biol. 2009, 566:123-135.
40. Mohás M., Kisfali P., Baricza E., Mérei A., Maász A., Cseh J., Mikolás E., Szijártó I.A., Melegh B., Wittmann I. A polymorphism within the fructosamine-3-kinase gene is associated with HbA1c Levels and the onset of type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes 2010, 118:209-212.
41. Butterfield D.A., Bader Lange M.L., Sultana R. Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease. Biochim. Biophys. Acta 2010, 1801:924-929.
42. Butterfield D.A., Reed T., Sultana R. Roles of 3-nitrotyrosine- and 4-hydroxynonenal-modified brain proteins in the progression and pathogenesis of Alzheimer's disease. Free. Radic. Res. 2011, 45:59-72.
43. Di Domenico F., Perluigi M., Butterfield D.A., Cornelius C., Calabrese V. Oxidative damage in rat brain during aging: interplay between energy and metabolic key target proteins. Neurochem. Res. 2010, 35:2184-2192.
44. Perluigi M., Di Domenico F., Giorgi A., Schininà M.E., Coccia R., Cini C., Bellia F., Cambria M.T., Cornelius C., Butterfield D.A., Calabrese V. Redox proteomics in aging rat brain: involvement of mitochondrial reduced glutathione status and mitochondrial protein oxidation in the aging process. J. Neurosci. Res. 2010, 88:3498-3507.
45. Calabrese E.J., Mattson M.P., Calabrese V. Dose response biology: the case of resveratrol. Hum. Exp. Toxicol. 2010, 29:1034-1037.
46. Calabrese E.J., Mattson M.P., Calabrese V. Resveratrol commonly displays hormesis:occurrence and biomedical significance. Hum. Exp. Toxicol. 2010, 29:980-1015.
47. Shaw J.E., Sicree R.A., Zimmet P.Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 2010, 87:4-14.
48. Bierhaus A., Hofmann M.A., Ziegler R., Nawroth P.P. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus I. The AGE concept. Cardiovasc. Res. 1998, 37:586-600.
49. Tsukahara H., Sekine K., Uchiyama M., Kawakami H., Hata I., Todoroki Y., Hiraoka M., Kaji M., Yorifuji T., Momoi T., Yoshihara K., Beppu M., Mayumi M. Formation of advanced glycosylation end products and oxidative stress in young patients with type 1 diabetes. Pediatr. Res. 2003, 54:419-424.
50. Wolf G. New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology. Eur. J. Clin. Invest. 2004, 34:785-796.
51. Dolhofer-Bliesener R., Lechner B., Deppisch R., Ritz E., Gerbitz K.D. Immunological determination of advanced glycosylation end-products in human blood and urine. Nephrol. Dial. Transplant. 1995, 10:657-664.
52. Schleicher E.D., Wagner E., Nerlich A.G. Increased accumulation of the glycoxidation product Nε-(carboxymethyl)lysine in human tissues in diabetes and aging. J. Clin. Invest. 1997, 99:457-468.
53. Daimon M., Ono Y., Saito T., Yamaguchi H., Hirata A., Ohnuma H., Igarashi M., Eguchi H., Manaka H., Kato T. Increased serum levels of pentosidine, but not carboxymethyl lysine, in type 2 diabetes without obvious diabetic nephropathy. Diabetes Care 1999, 22:877-878.
54. Miyata T., Van Ypersele De C., Strihou K., Kurokawa J.W.Baynes Alterations in nonenzymatic biochemistry in uremia: origin and significance of carbonyl stress. in long-term uremic complications. Kidney Int. 1999, 55:389-399.
55. Beisswenger P.J., Drummond K.S., Nelson R.G., Howell S.K., Szwergold B.S., Mauer M. Susceptibility to diabetic nephropathy is related to dicarbonyl and oxidative stress. Diabetes 2005, 54:3274-3281.
56. Rösen P., Nawroth P.P., King G., Moller W., Tritschler H.J., Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications. Diabetes Metab. Res. Rev. 2001, 17:189-212.
57. Folli F., Corradi D., Fanti P., Davalli A., Paez A., Giaccari A., Perego C., Muscogiuri G. The Role of Oxidative Stress in the Pathogenesis of Type 2 Diabetes Mellitus Micro- and Macrovascular Complications:Avenues for a Mechanistic-Based Therapeutic Approach. Curr. Diabetes Rev. 2011, 7:313-324.
58. Lauderback C.M., Hackett J.M., Huang F.F., Keller J.N., Szweda L.I., Markesbery W.R., Butterfield D.A. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1-42. J. Neurochem. 2001, 78:413-416.
59. Morrow J.D., Roberts L.J. The isoprostanes. Current knowledge and directions for future research. Biochem. Pharmacol. 1996, 51:1-9.
60. Gopaul N.K., Anggard E.E., Mallet A.I., Betteridge D.J., Wolff S.P., Nourooz-Zadeh J. Plasma 8-epi-PGF 2 alpha levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Lett. 1995, 368:225-229.
61. Mori T.A., Dunstan D.W., Burke V., Croft K.D., Rivera J.H., Beilin L.J., Puddey I.B. Effect of dietary fish and exercise training on urinary F2-isoprostanes excretion in non-insulin-dependent diabetic patients. Metabolism 1999, 48:1402-1408.
62. Mancuso C., Scapagnini G., Currò D., Giuffrida Stella A.M., De Marco C., Butterfield D.A., Calabrese V. Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. Front. Biosci. 2007, 12:1107-1123.
63. Pepicelli O., Fedele E., Berardi M., Raiteri M., Levi G., Greco A., Ajmone-Cat M.A., Minghetti L. Cyclo-oxygenase-1 and -2 differently contribute to prostaglandin E2 synthesis and lipid peroxidation after in vivo activation of N-methyl-D-aspartate receptors in rat hippocampus. J. Neurochem. 2005, 93:1561-1567.
64. Mancuso C., Pani G., Calabrese V. Bilirubin: an endogenous scavenger of nitric oxide and reactive nitrogen species. Redox Rep. 2006, 11:207-213.
65. Holmgren A. Thioredoxin. Annu. Rev. Biochem. 1985, 54:237-271.
66. Yamawaki H., Berk B.C. Thioredoxin: a multifunctional antioxidant enzyme in kidney, heart and vessels. Curr. Opin. Nephrol. Hypertens. 2005, 14:149-153.
67. Chen Z.H., Saito Y., Yoshida Y., Sekine A., Noguchi N., Niki E. 4-Hydroxynonenal induces adaptive response and enhances PC12 cell tolerance primarily through induction of thioredoxin reductase 1 via activation of Nrf2. J. Biol. Chem. 2005, 280:41921-41927.
68. Pitocco D., Zaccardi F., Di Stasio E., Romitelli F., Santini S.A., Zuppi C., Ghirlanda G. Oxidative stress, nitric oxide, and diabetes. Rev. Diabet. Stud. 2010, 7:15-25.